TP53 and non-small cell lung carcinoma: The same trend has been shown in other studies, for instance KRAS mutations were less frequent in the younger population as shown by Tanaka et al (2% vs 10%), as well as by Sacher et al.1, 2, 17 In our analysis, no fundamental difference was shown with regard to the frequency of alterations in TP53 between young and older patients, which is in agreement with previous studies, which did not detect genetic variants of TP53 in 16 out of 17 young (age range: 25‐41 years) and 10 out of 11 older (age range: 68‐82 years) NSCLC patients.17